Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Many targeted NGS-based panels have recently been introduced to detect RNA fusions useful for prognosis and therapy selection in cancer. Understanding the lower limits of detection (LOD) and the reproducibility across the reportable range of these assays is important for clinical adoption and regulatory compliance. However, there are few tools available to assess LOD. We generated an RNA panel that represents decreasing levels of 16 different RNA fusions and exam skipping events compared to the total cellular RNA.

Sponsored by

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.